Liontown Resources Ltd (ASX: LTR) and Mesoblast Ltd (ASX: MSB) are two of four ASX shares falling on Friday. Here's ...

Top 2024 performers include multiple health care stocks with unique catalysts, as well as several quantum computing ...

S&P/ASX All Ords Index (ASX: XAO) shares closed higher on the first day of trading for 2025, with these stocks clocking new ...

New data shows the 40 key ASX biotechs gained an average 50% in 2024 - but not all of them joined the winner's circle.

Mesoblast's FDA approval for remestemcel marks a milestone for MSC therapies, but limited cash reserves pose risks for US ...

Remestemcel-L is under clinical development by Mesoblast and currently in Phase III for Crohn's Disease (Regional Enteritis).

Morgans's healthcare analyst Iain Wilkie describes 2024 as "pretty patchy" for the ASX healthcare sector, which has ...

INR:0580. blackjack en ligne gratuity The National Health Commission issued a document: Grassroots doctors with a secondary technical school degree or ...

INR:1697. rummy mind Anti-inflammatory cell therapy Ryoncil was approved by the US FDA expert panel with a high vote! China's first! Legend Biotech's CAR-T therapy is ...

INR:0064. karnataka cricket team vs rajasthan cricket team match scorecard Anti-inflammatory cell therapy Ryoncil ...

Amigo Fruits 5 uses in hindi Anti-inflammatory cell therapy Ryoncil was approved by the US FDA expert panel with a high vote! Osimertinib r ...

The allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy Ryoncil (remestemcel-L-rknd) has been approved for ...